New research suggests that certain patients with low-risk thyroid cancer can safely forgo postoperative radioiodine ablation ...

The purpose of these estimates is to inform state and local cancer care organizations and providers, patient support programs ...

Immune checkpoint inhibitors have changed the future of cancer care. These powerful treatments use the body’s own immune ...

Exelixis (EXEL) moves to 'Buy' with a de-risked pipeline, strong financials, and breakthrough phase 3 results. See more analysis here.

A study led by UCLA has discovered that JAK inhibitors could potentially prevent or reverse immune-related diabetes triggered ...

A woman who was diagnosed with thyroid cancer at the age of 20 in 2022 was initially brushed off by doctors with her symptoms ...

Survival rates in cancer patients on immune checkpoint inhibitors depended on their insurance coverage, new study found.

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

Key Takeaways Powerful immunotherapies are dramatically improving odds of surviving cancerHowever, people without insurance ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

The addition of metformin “was generally well tolerated but did not result in the targeted benefit of a 20% reduction in risk of death in an unselected population,” the researchers wrote.